Partner with BrainTest®
Sign up and learn more about how you can benefit by working with BrainTest
Digital version of the Self-Administered Gerocognitive Examination eSAGE (BrainTest) made for tablets shows no scale bias compared to the validated SAGE.
- eSAGE has the advantage of self- administration, brevity, four interchangeable forms and potential widespread availability to be a major factor in overcoming the many obstacles in identifying early cognitive
changes in individuals.
- Abstract was presented in April 2017 at the American Academy of Neurology Conference. The Official Journal of the American Academy of Neurology
Researchers at Ohio State University Wexner Medical Center, evaluated study participants using SAGE and then evaluated the same subjects with other established assessment tools:
- The test has a sensitivity of 79% and a false positive rate of 5% percent in detecting cognitive impairment from normal subjects
- Results were published in the January-March 2010 issue of Alzheimer’s Disease & Associated Disorders.
Another study investigated the functionality of SAGE for cognitive screening in community settings and examined its characteristics as a cognitive screening assessment tool.
- From 45 community events, 1,047 individuals over age 50 were screened. Cognitive impairment was identified in 28%.
- Principal-component and correlation analysis indicate that SAGE is an internally-consistent test that is very well balanced, with language, cognition, visuospatial, executive, and memory domains
- Community cognitive screening was found to be feasible and efficient in diverse settings
- Results were published in The Winter 2014 Journal of Neuropsychiatry & Clinical Neurosciences.
A study determined that repetitively giving SAGE over time provides significant diagnostic assistance
for clinicians.
- SAGE scores over time in individuals remained stable in subjective and mild cognitive impairment that did not convert to dementia. Those with declining SAGE scores were at high risk for dementia diagnosis.
- Abstract was presented in April 2015 at the American Academy of Neurology Conference. The Official Journal of the American Academy of Neurology
An Abstract presented in 2015 at the Alzheimer’s Association International Conference demonstrated that the paper-based test (SAGE) or electronic format (BrainTest) can be used without statistical difference.
BrainTest Team
Frederick Ghahramani
Founder, BrainTest
Michael Kader
President & Legal Counsel
Terence Lee
Director of Product
Don Roth
Director of Research
Michael Rubin
Director of Business Development
John Shwaluk
Technical Lead
BrainTest Medical Advisory Board
Dr. Scharre, MD
Head of Medical Affairs
Ohio State University
Dr. Borson, MD
Psychiatry
University of Washington
Dr. Cummings, MD, ScD
Neurology
Cleveland Clinic
Dr. Grover, MD, MPA
Epidemiology
McGill University
Dr. Tangalos, MD
Geriatric & Internal Medicine
Mayo Clinic
Dr. Tariot, MD
Neuropharmacology
Banner Alzheimer’s Institute
Dr. Trzepacz, MD
Medical Executive
Indiana University
Marc Wortmann
CEO, Marc Wortmann Consultancy
Former Executive Director, Alzheimer's Disease International
